Frontotemporal dementia (FTD) and Alzheimer's disease are distinct brain disorders, and the fastest clues that separate them are personality/language changes, memory, and age of onset. FTD usually begins with shifts in behavior or speech in people in their late 40s to early 60s, while Alzheimer's most often begins with memory loss after age 65. FTD is an umbrella term for disorders caused by damage to the frontal and temporal lobes—the brain regions that govern personality, behavior, and language. According to the National Institute on Aging, it is a leading cause of dementia in people under 65, which makes early age of onset one of the strongest signals that a diagnosis may be FTD rather than Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- The first symptom is the clearest clue
- The two main forms of FTD
- Age of onset and how common each is
- Why FTD is often misdiagnosed
- What's in the treatment pipeline
- Frequently Asked Questions
The first symptom is the clearest clue
The earliest sign is often the most telling difference. In Alzheimer's, the hallmark first symptom is memory loss—forgetting recent conversations, appointments, or names. In FTD, memory is often relatively intact early on, while personality, judgment, or language change first.
The Alzheimer's Association notes that FTD's earliest signs are behavioral changes or a decline in speaking and understanding language. A person with FTD may act inappropriately in public or lose interest in loved ones long before they misplace their keys. So when a family notices someone "isn't acting like themselves" before any memory problem appears, that pattern points more toward FTD than Alzheimer's.
The two main forms of FTD
FTD is not a single condition. It has two main forms, and knowing which one you're seeing helps clarify the picture.
The Alzheimer's Association describes both forms as damage centered in the frontal and temporal lobes. By contrast, Alzheimer's typically spreads from memory centers outward, so word-finding and behavior problems tend to arrive later, not first.
- **Behavioral-variant FTD (bvFTD):** apathy, disinhibition, loss of empathy, and poor judgment. The person may seem rude, impulsive, or emotionally flat.
- **Primary progressive aphasia (PPA):** a steady decline in speaking, naming objects, or understanding words, while other thinking skills stay stronger early on.
Age of onset and how common each is
Age is a practical dividing line. FTD symptoms usually begin between ages 45 and 64, notably younger than typical Alzheimer's, which most often appears after age 65, per the National Institute on Aging. Prevalence differs sharply too.
The Alzheimer's Association estimates about 50,000 to 60,000 Americans have bvFTD or PPA, most aged 45 to 65. Alzheimer's is far more common: an estimated 6.9 million Americans 65 and older live with Alzheimer's dementia, with roughly 200,000 more under 65 who have younger-onset dementia. The takeaway: in a younger adult with behavior or language changes, FTD deserves serious consideration even though it is the rarer disease overall.
Why FTD is often misdiagnosed
Because FTD starts with behavior and strikes younger people, it is frequently mistaken for something else. The National Institute on Aging warns that FTD is often misdiagnosed as Alzheimer's, depression, or a psychiatric disorder. This matters for treatment.
There are no FDA-approved drugs to slow or cure FTD, and care is symptomatic. Alzheimer's-specific drugs such as cholinesterase inhibitors are not indicated for FTD and may actually worsen symptoms—so an incorrect Alzheimer's diagnosis can lead to unhelpful medication. If early symptoms are behavioral or language-based rather than memory-based, it is reasonable to ask a clinician directly whether FTD has been considered and ruled out.
What's in the treatment pipeline
No approved therapy changes the course of FTD today, but research is moving. In February 2024, the FDA granted latozinemab Breakthrough Therapy Designation, according to its developer Alector, for FTD caused by a progranulin (GRN) gene mutation.
Read that carefully: this is an investigational Phase 3 antibody, not an approved treatment, and the designation is a regulatory step meant to speed review—not proof it works. Families interested in emerging options can ask a neurologist about clinical trial eligibility rather than waiting for a pharmacy prescription.
Frequently Asked Questions
Can someone have both FTD and Alzheimer's?
A definitive diagnosis can be difficult, and overlapping symptoms are one reason FTD is often misdiagnosed. A neurologist uses history, imaging, and testing to distinguish them.
Does memory loss rule out FTD?
Not entirely, but prominent early memory loss points more toward Alzheimer's. In FTD, behavior or language changes usually come first, per the National Institute on Aging.
Should Alzheimer's medications be tried for FTD?
No. The NIA notes cholinesterase inhibitors are not indicated for FTD and may worsen symptoms, so a correct diagnosis matters before starting any drug.
